CSE:DRUG - Post Discussion
Post by
OTCLegenda on Sep 19, 2022 1:51pm
There’s been a lot of buzz about psychedelic stocks lately
DRUG has actually kept the gains it made on its mid-August sympathy run.
The psychedelic sector hasn’t caught fire like marijuana and biotechs have in the past couple years.
It lacks the potential for the kind of big-business recreational sector marijuana is developing. And the diseases that psychedelics treat, like depression and PTSD, aren’t as visible as cancer…
But more places in the US keep legalizing psychedelic therapies. Depression affects more Americans than cancer does — and psychedelics are increasingly seen as a breakthrough treatment.
Be the first to comment on this post